🇺🇸 FDA
Patent

US 11826386

Compositions and methods for treating cancer

granted A61KA61K2039/876A61K2239/31

Quick answer

US patent 11826386 (Compositions and methods for treating cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/876, A61K2239/31, A61K2239/38, A61K2239/57